| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | OI1; OI2; OI3; OI4; EDSC; CAFYD; EDSARTH1; COL1A1; Collagen I |
| Entrez GeneID | 1277 |
| WB Predicted band size | 139 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Recombinant protein of human Collagen I |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于COL1A1抗体的3篇文献示例(虚构内容，仅作格式参考)：
1. **文献名称**：《COL1A1抗体在纤维化疾病中的诊断应用》
**作者**：Smith A et al.
**摘要**：研究验证了抗COL1A1抗体在肝纤维化和肺纤维化患者血清中的特异性表达，发现其水平与纤维化程度呈正相关，提示其作为无创诊断标志物的潜力。
2. **文献名称**：《靶向COL1A1的抗体抑制肿瘤基质重塑的机制研究》
**作者**：Chen L et al.
**摘要**：通过构建靶向COL1A1的单克隆抗体，证明其可阻断胶原蛋白沉积，抑制肿瘤微环境中的基质硬化，增强化疗药物在胰腺癌模型中的渗透性。
3. **文献名称**：《COL1A1抗体在成骨不全症中的功能分析》
**作者**：Yamamoto K et al.
**摘要**：利用COL1A1多克隆抗体检测成骨不全症患者突变胶原蛋白的异常分泌，揭示部分基因突变导致胶原交联缺陷，为疾病分型提供依据。
(注：以上为模拟内容，实际文献需通过PubMed/Google Scholar等平台检索。)
The COL1A1 antibody targets the alpha-1 chain of type I collagen, encoded by the COL1A1 gene. Type I collagen, the most abundant structural protein in vertebrates, is a fibrillar collagen critical for providing tensile strength to connective tissues such as skin, bone, tendons, and organs. It forms a heterotrimer comprising two α1 chains (COL1A1) and one α2 chain (COL1A2), synthesized as precursor procollagen molecules that undergo post-translational modifications before extracellular assembly into fibrils.
COL1A1 antibodies are essential tools in biomedical research and diagnostics. They are widely used to study collagen expression, localization, and abnormalities in diseases like osteogenesis imperfecta (caused by COL1A1 mutations), fibrosis, and cancers, where altered collagen deposition contributes to tissue stiffening or metastasis. These antibodies enable detection via techniques including immunohistochemistry (IHC), Western blotting, and immunofluorescence.
In pathological contexts, COL1A1 upregulation is associated with fibrotic disorders (e.g., liver cirrhosis, pulmonary fibrosis) and tumor microenvironments, while downregulation or mutations may impair bone mineralization. Commercial COL1A1 antibodies are typically raised in hosts like rabbits or mice, with monoclonal variants offering high specificity. Validation across species and applications ensures reliability in both research and clinical settings, aiding mechanistic insights and therapeutic targeting of collagen-related pathologies.
×
